U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset
Reuters reports that a U.S. judge cited a pattern of misconduct by Merck & Co, which released Gilead Sciences from paying any damages for infringing Merck's patents on its hepatitis C treatments, Sovaldi and Harvoni.
This ruling follows a March 24th order from a federal jury that said Gilead had to pay $200M in damages to Merck.
Read the Reuters story